[Protease inhibitors in the treatment of chronic hepatitis C]

Comment

. 2007 Oct;45(10):1085-8.

doi: 10.1055/s-2007-963473.

[Article in German]

Comment

[Article in German]

J Vermehren et al. Z Gastroenterol. 2007 Oct.

. 2007 Oct;45(10):1085-8.

doi: 10.1055/s-2007-963473.

No abstract available

Comment on

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study.
Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, McNair L, Purdy S, Kauffman R, Alam J, Jansen PL. Reesink HW, et al. Gastroenterology. 2006 Oct;131(4):997-1002. doi: 10.1053/j.gastro.2006.07.013. Gastroenterology. 2006. PMID: 17030169 Clinical Trial.
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J, Zeuzem S. Sarrazin C, et al. Gastroenterology. 2007 Apr;132(4):1270-8. doi: 10.1053/j.gastro.2007.01.041. Epub 2007 Jan 25. Gastroenterology. 2007. PMID: 17408662 Clinical Trial.
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.
Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S. Forestier N, et al. Hepatology. 2007 Sep;46(3):640-8. doi: 10.1002/hep.21774. Hepatology. 2007. PMID: 17879366 Clinical Trial.